Markets

Genmab’s Phase 3 RAINFOL-02 Trial Meets Primary PFS And Key Secondary OS Endpoints, Demonstrating A Statistically Significant And Clinically Meaningful Improvement For Rina-S In Platinum-Resistant Ovarian Cancer

Oct 23, 2026 · 11:57 AM ET· updated 1h ago

Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator’s choice

Why It Matters

Genmab's new cancer medicine passed its biggest test in ovarian cancer patients. When a medicine passes its main test, it means the company is closer to selling it and helping patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

GMAB42.03

+2.03 (+5.08%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.